Chief Executive Officer

Dr. Eva Steiness

is an M.D., D.Sci. and tenure Professor of Clinical Pharmacology. She has more than 10 years of clinical experience in medicine and has been Dean of Medical Faculty at Copenhagen University, Denmark. For the 89-98 decade, she was responsible for R&D in the pharmaceutical company H. Lundbeck A/S as Executive Vice President and member of the board of management. She made a turnaround of R&D, brought two compounds to market, and created a pipeline with compounds both in clinical development and drug discovery. These accomplishments resulted in a very successful IPO in 1999. In 1998, she founded and managed as Chief Executive Officer Zealand Pharma A/S. Based on three patent applications, Zealand Pharma brought six compounds into development, three of which were out-licensed to Sanofi-Aventis and to Wyeth. In 2008, Eva Steiness founded as CEO newpharma.dk, a consultancy company offering management to biotech companies in which capacity she has served for Phlogo ApS, Serodus ASA, and Neoloch ApS. She is on the board of Photocure ASA, Bio-Medisinsk Innovasjon AS, Phlogo ApS, and The Oticon Foundation. She has also had several positions of trust in the Danish Ministry of Technology, Research and Innovation. Send e-mail

Chief Operational Officer

Dr. Trygve Gulbrandsen

holds a D. Sc. in chemistry from the University of Oslo. During his 17 years in Nycomed Imaging (GE Health), Dr. Gulbrandsen held positions as responsible for chemical process development and technology transfer, Project Manager of Visipaque and Teslascan and later as Vice President of Licensing. During his stay at Nycomed he completed the Post-Graduate Course of Pharmaceutical Medicine at the University of Leiden, a 9 week intensive course in preclinical and clinical pharmacology. During his 4 years at Medinnova Dr. Gulbrandsen gained experience in patenting and public financing of early phase commercialisation of university innovations. Dr. Gulbrandsen was the CEO of BMI during its first year of operations and project manager for BMI's clinical study on piboserod in heart failure patients. He was also the CEO of Serodus through 2008. Send e-mail